Logo

Aruna Bio Reports IND Clearance of AB126 from the US FDA for Neurological Indications

Share this
Aruna Bio

Aruna Bio Reports IND Clearance of AB126 from the US FDA for Neurological Indications

Shots:

  • The US FDA has cleared the IND application of AB126 to conduct a P-Ib/IIa study for the treatment of acute ischemic stroke and expected to initiate in H1’24
  • The P-Ib/IIa dose-ascending study investigating the safety, tolerability, and preliminary efficacy of AB126 (3 IV doses at low, medium, and high doses) for the treatment of acute ischemic stroke that has undergone a thrombectomy
  • AB126, an unmodified neural-derived exosome, possesses an innate ability to cross the blood-brain barrier and exhibits anti-inflammatory and neuroprotective properties

Ref: Globenewswire | Image: Aruna Bio

Related News:- Cure Genetics Signs a Collaboration and License Agreement with Frametact to Develop Gene Therapy for Familial Neurological Diseases

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions